Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative…
Year: 2022
Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children’s Research Institute
Highlights: Recce’s new Anti-Infective Research Unit located within Murdoch Children’s world-leading research facilities – internationally…
Black Diamond Therapeutics Announces Changes to Board of Directors
CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Aruna Bio Announces Appointment of Mike Ryan to its Board of Directors
BOSTON and ATHENS, Ga., Dec. 19, 2022 (GLOBE NEWSWIRE) — Aruna Bio, Inc., a leader…
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) — Connect Biopharma Holdings…
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
Regulatory submission for the expanded indication is supported by data from two recently completed 4-week…
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
Tislelizumab supplied by BeiGene as part of ImmixBio’s Clinical Trial and Supply Agreement with BeiGene…
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
Appointment brings more than 20 years of life sciences finance leadership experience to the CFO…
Vaxart Names Phillip Lee as Chief Financial Officer
Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more…
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
Funding from three leading healthcare investors, with Vivo Capital joining existing investors Nantahala Capital and…
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight…
Oncotelic Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
–Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif.,…
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly…
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI)…
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc
NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the…
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly…
Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield
100% Survival Rate in Anthrax-infected Rabbits Treated with Omadacycline Total Revenue Recognition to Paratek of…
Cronos Group Inc. Announces Receipt of Notice of Relinquishment of Warrant by Altria
TORONTO, Dec. 19, 2022 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”…
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
Glofitamab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for…
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes…